1. Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study imbalance in exacerbation rate (-19.4% (p = 0.153) reduction unadjusted); ¶: p = 0.042, exacerbat...
Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study imbalance in exacerbation rate (-19.4% (p = 0.153) reduction unadjusted); ¶: p = 0.042, exacerbation rate 26.2% lower in omalizumab group; +: p = 0.002, exacerbation rate 50.0% lower in omalizumab group. Reproduced, with modifications, from [1] with permission from the publisher.
R. Buhl Eur Respir Rev 2007;16:73-77
©2007 by European Respiratory Society